Adjuvant Trastuzumab for HER2-positive early breast Cancer: A review of clinical data with nursing implications

Frances M. Palmieri, Charlyn V. Myatt, Edith A. Perez

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

This article reviews clinical data on adjuvant trastuzumab (Herceptin®, Genentech, Inc.) for patients with HER2-positive early breast cancer. Published articles were searched via PubMed (1985-2009), and abstracts were located from meeting books or search engines of congress Web sites (1994-2009). Search terms included breast neoplasms, breast cancer, breast tumor, or breast tumour and adjuvant plus HER2-positive plus trastuzumab. Trastuzumab improves clinical outcomes as well as disease-free and overall survival for patients with early HER2-positive breast cancer compared with adjuvant chemotherapy alone in this population. Trastuzumab has a favorable safety profile; levels of cardiac dysfunction were acceptable in all adjuvant trials, and cardiac dysfunction was manageable in most cases. Awareness of the clinical data will help nurses identify patients eligible for adjuvant trastuzumab, familiarize them with treatment and cardiac monitoring plans, and provide them with information to help advise, treat, and support patients from diagnosis through completion of therapy.

Original languageEnglish (US)
Pages (from-to)326-336
Number of pages11
JournalClinical journal of oncology nursing
Volume14
Issue number3
DOIs
StatePublished - Jun 1 2010

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)

Fingerprint Dive into the research topics of 'Adjuvant Trastuzumab for HER2-positive early breast Cancer: A review of clinical data with nursing implications'. Together they form a unique fingerprint.

  • Cite this